WIC
ALXN

Woodmont Investment Counsel’s Alexion Pharmaceuticals ALXN Stock Holding History

Woodmont Investment Counsel’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-38
Closed -$5K – 675
2016
Q3 		$5K Buy
+38
New +$4.89K ﹤0.01% 570

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Woodmont Investment Counsel's ALXN Position: Q4 2016 in Review

Woodmont Investment Counsel sold out of Alexion Pharmaceuticals (ALXN) in Q4 2016, closing a stake of 38 shares — an estimated $5K sold.

Woodmont Investment Counsel first reported a position in ALXN in Q3 2016 and held it in 1 quarter. The position peaked at $5K in Q3 2016. 549 funds tracked by Wall St. Rank hold ALXN as of Q4 2016.

  • Woodmont Investment Counsel reported no remaining Alexion Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Woodmont Investment Counsel sold 38 Alexion Pharmaceuticals shares in Q4 2016, an estimated $5K.
  • Woodmont Investment Counsel first reported a position in Alexion Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Woodmont Investment Counsel's Alexion Pharmaceuticals position peaked at $5K in Q3 2016.
  • 549 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2016.

Based on Woodmont Investment Counsel's 13F filing for Q4 2016, filed 13 Feb 2017.